Purpose: The aim of this study was to quantify the reduction of perceived pain levels during lymphoscintigraphy for melanoma by altering the pH of the 99m Tc-sulfur colloid to near the physiologic value of 7.40. Patients and Methods: This is an institutional review board-and Food and Drug Administration-approved randomized, double-blinded, prospective crossover trial, registered with clinicaltrials.org. Before beginning the procedure and after signing informed consent, 60 serial enrollees presenting for sentinel lymph node imaging of melanoma of the thorax and appendicular structures completed a questionnaire addressing background information, administered by a research support nurse. An investigator (N.H.) prepared the injections to be used and labeled them such that no one else could discover which injections contained standardof-care solution and which contained the pH-altered solution (buffered to near pH 7.40 using sodium bicarbonate). After each injection, the enrollee was asked by a research support nurse to quantify the pain of each injection using a scale of 0 to 10. The injection site location (head, thorax, appendicular structures, and other) was also recorded. Results: Sixty subjects were enrolled in the study, of which 57 had complete data. On average, there was a significant mean (SD) decrease of 1.42 (2.17) points (95% confidence interval, 0.85-2.00) on a pain scale of 0 to 10 when the buffered injections were used as compared with the standard-of-care injections (P < 0.0001). Ordering of injections did not significantly affect perceived pain scores. Conclusions: The use of sodium bicarbonate to buffer the pH of 99m Tcsulfur colloid to near the physiologic value of 7.40 significantly reduced perceived pain levels during nonbreast lymphoscintigraphy.
A pproximately weekly, patients present to our institution for a melanoma sentinel lymph node (SLN) lymphoscintigraphy. Classically, 4 injections of 99m TC-sulfur colloid (SC) are administered intradermally. The injections are in the immediate vicinity of a dermatologic malignancy or biopsy site. This allows for the identification of SLNs in anticipation of surgical removal. The procedure, while well tolerated in general, is consistently associated with pain and stinging at the injection site.
Pain during breast SLN procedures has been reported to be as high as 8.8/10. 1 The literature suggests that the use of bicarbonate to alkalinize the injected radiopharmaceutical can safely reduce perceived pain from 6.6/10 to 4.7/10 in breast SLN procedures while not significantly effecting SLN identification. 2, 3 Rather than buffering the SC injectate to minimize pain in breast SLN, some institutions consider using lidocaine chloride for local anesthesia. Note, however, that lidocaine chloride in and of itself can be painful on injection, with a reported pain rating of 7.6/10. 4 It has been common practice in emergency rooms to buffer lidocaine chloride at a ratio of 1:10 with bicarbonate to reduce the "burning" pain from lidocaine's acidic nature. 5 Similarly, 99m Tc-SC is normally acidic with approximately pH 6.04. 2 As an alternate to 99m Tc-SC, 99m Tc-human serum albumin may be used for SLN localization. Others have compounded 99m Tc-human serum albumin with lidocaine chloride in an effort to minimize pain, but it is known that this process may result in a decline of stability in the mixture. 6 Moreover, the time to onset of anesthetic effect of lidocaine chloride has been described to be in the 2-minute range, 7 which necessitates an inconvenient procedural delay. Initial laboratory work revealed that a similar approach to altering the pH of 99m Tc-SC did not significantly reduce the stability of the 99m Tc-SC (data not shown).
In the present study, we investigated whether the perceived pain level during SLN techniques could be reduced by raising the pH of 99m Tc-SC to near the physiologic level of pH 7.40.
PATIENTS AND METHODS

Patients
Between August 2012 and December 2014, a total of 60 patients with melanoma who presented for SLN evaluation volunteered to be enrolled in this study. Male and female patients of all races and ethnicities, aged 18 years and older, who presented for SLN imaging for melanoma or who had undergone an excisional biopsy for melanoma of the thorax and/or appendicular structures and who were scheduled to receive 2 or more injections of 99m Tc-SC, were considered eligible for inclusion. Patients were excluded from enrollment if they were presenting for SLN imaging of lesions involving the breast, ear, nose, or genitourinary regions; if they were scheduled to receive only a single injection of 99m Tc-SC; and if pregnant or breast-feeding.
Study Design and Procedures
The study was approved by the local institutional review board and by the US Food and Drug Administration as an investigational new drug and was registered with clinicaltrials.org as randomized, double-blinded, and prospective crossover in design.
Before beginning the procedure and after signing informed consent, 60 serial subjects were asked by a blinded research support assistant to fill out a questionnaire addressing background information ( Fig. 1 ). Before the first injection and after each subsequent injection, the subject was asked to quantify the pain of every injection using a validated scale from 0 through 10, with 0 being no pain and 10 being severe pain that is disabling (ie, unable to perform activities of daily living; Fig. 2 ).
Randomization
Subjects were randomized into 1 of 2 sequence groups (A and B): Sequence group A. The first injection administered was the standard-of-care (SOC) solution followed by the pH-altered solution. The remaining injections were randomly assigned as either SOC solution or pH-altered.
Sequence group B. The first injection administered was the pHaltered solution followed by the SOC solution. The remaining injections were randomly assigned as either SOC solution or pH-altered.
The technique of permuted block randomization was used to assign subjects to sequence groups while ensuring that group sizes were similar. The randomization procedure was also stratified according to the following broadly defined sites of injection to ensure relatively equal distribution of them among the sequence groups: microvolume pH meter for confirmation, then prepared the injections and labeled them, in separate syringes, such that the physician, nuclear medicine technologist, or health care professional (not involved in the data assessment) performing the SLN injections was blinded as to which injections contained SOC solution and which contained the pH-altered solution. Before any administration to subjects, all buffered injections were run through a 0.22-μm filter for cold sterilization, as required by the Food and Drug Administration under the Investigational New Drug protocol.
The maximum activity injected was 1.0 mCi with a maximum volume of 1.0 mL. Neither the addition of sodium bicarbonate nor the alteration of the pH resulted in any discernible change in the observable characteristics of the injectate; there was no clouding, color change, or precipitate formation.
The procedure for injection of 99m Tc-SC was in accordance with the community-based SOC. This study did not change the procedure; it only changed the pH of the solute being injected during a randomized number of injections.
For the purposes of this study, the protocol was ended for each subject upon completion of the final pain assessment. The subject then continued on to the SOC imaging and continued clinical management.
Safety Assessments
Injection site pain of 8 of 10 or less was not considered an adverse event. Injection site pain of 9/10 or 10/10 was considered an adverse event. All adverse events were appropriately documented and reported to the institutional review board in accordance with institutional policy. Eleven of 60 subjects reported significant pain, warranting an adverse event determination. Upon limited breaking of blinding, to investigate the adverse event, all adverse events were found to have the significant pain directly related to the SOC solution and not due to the pH altered solutions. No other adverse events were identified.
Statistical Considerations
The data obtained from the first 2 injections were used to assess the efficacy of the buffered solution in reducing injection pain. One concern with this design is that since the pain assessments were Reducing Pain During Lymphoscintigraphy made within minutes of 1 another, estimate of the treatment effect may be biased due to the effect of "carry-over." To evaluate this, we analyzed the data using the 2-staged approach proposed by Grizzle. 8 The first step in the process was to assess the magnitude of the carry-over effect, which was accomplished by comparing the sequence groups with respect to the mean of the period sums. These mean sums were subsequently compared using a 2-sample t test. We found that the carry-over effect was not significant at the 5% level (mean, 1.0.2; 95% confidence interval, −1.20 to 3.25; P > 0.36). The effect of treatment was estimated by taking the difference of the mean buffered and SOC pain scores, and a paired t test was used to test whether the mean difference was significantly different from 0. An α-level of 5% was used to determine the statistical significance of this test.
RESULTS
Patient Characterization
Fifty-seven of 60 enrolled subjects completed the study with usable data. Subject demographic data are summarized in Table 1 . As reported in other studies, 9 age was not associated with change in perceived pain level (Pearson correlation coefficient r = 0.026; 95% confidence interval, −0.28 to 0.24; P ≥ 0.85). Histories of nicotine use, regular or recent "pain medication" use, and having had a similar procedure all failed to demonstrate statistical significance ( Table 2) .
Changes in Perceived Pain Levels
After administration of the SOC injectate, a mean (SD) perceived pain of 5.81 (2.24) was observed as compared with 4.39 (2.45) after the pH-altered injectate. Using a paired t test, the mean (SD) decrease in perceived pain level of 1.42 (2.17) was found to be statistically significant (P < 0.0001; 95% confidence interval, 0.85-2.00). There seems to have been a difference between males and females with respect to perceived pain reduction. Males reported a mean pain reduction of 2.1, and females reported a mean pain reduction of only 0.6 (P = 0.0117; Table 3 ).
Moreover, anatomic injection site contributed to changes in perceived pain levels, with appendicular injections having an associated mean pain reduction of 1.9. The remaining anatomic regions of injection sites failed to have an associated significant change in perceived pain level (Table 4 ).
DISCUSSION
Using sodium bicarbonate to alter the pH of 99m Tc-SC to near the physiologic value of 7.40 during nonbreast lymphoscintigraphy performed for melanoma evaluation resulted in mean perceived pain score decreases from 5.81 to 4.39 (P < 0.0001). Males were more likely to perceive reduced pain with buffering than females (P = 0.0117), and when injected into appendicular regions, patients were more likely to perceive reduced pain with buffering. Ordering of injections had no significant "order" effect.
Although topical anesthetic creams should reduce perceived pain level, in theory, they have been found to have mixed results during breast SLN biopsies. 1, 10 The use of 99m Tc-nanocolloid is a practice in other countries, and it has been reported to have only mild discomfort. 11, 12 Moreover, a recently made available commercial compound is reported to have significant pain in only 0.2% of patients. 13 Limitations A few limitations are identified. We did not assess the time to first lymph node visualization, as this study was concerned primarily with reduction of pain rather than imaging performance. Further study to confirm noninferiority of buffered injectate may be useful, although it is not anticipated that solution buffering would adversely affect lymph flow and particle trafficking. Although not directly applicable to intradermal injections, the literature on neutral versus buffered solutions in peritoneal lymphatic handling has suggested that neutral solution kinetics are equivalent to those of acidic solutions. 14 In addition, a sample size of 60 may be inadequate to generalize to all practices. We utilized strict inclusion criteria and enrolled only those requiring more than 1 injection, for evaluation of melanoma, and not in the following regions: breast, ear, nose, and genitourinary. Future application to a broader patient population may be of benefit.
Future Considerations
A side-by-side cost comparison with new commercially available compounds may be prudent. Furthermore, developing a "thumb-rule" of quantity needed to effect a near physiologic buffering, instead of using a specific pH meter, would be useful. Lastly, evaluation of this technique for patients with other dermatologic malignancies, those requiring only a single injection site, and those with pathology in the breast, ear, nose, and genitourinary regions may prove insightful.
